

HyQvia (Immune Globulin 10% w/ Hyaluronidase)
Subcutaneous Prescriber Order Form – Adult & Pediatrics

Patient Name: _____	DOB: _____	Gender: _____
----------------------------	-------------------	----------------------

Address: _____

Phone: _____	Height: _____	Weight: _____
---------------------	----------------------	----------------------

Clinical Information

Primary Diagnosis Description: _____	ICD-10 Code: _____
---	---------------------------

HyQvia:

Infuse _____ gm (target dose*) subcutaneously every _____ weeks after the initial ramp up per package insert.

HyQvia-naïve; initial ramp up as below. Prior HyQvia target dose reached; no ramp up required.

Infusion Number	Week	Every ___ Week Interval	Dose
<input type="checkbox"/> 1 st infusion	Week _____	_____ % of target dose*	_____ grams
<input type="checkbox"/> 2 nd infusion	Week _____	_____ % of target dose*	_____ grams
<input type="checkbox"/> 3 rd infusion	Week _____	_____ % of target dose*	_____ grams
<input type="checkbox"/> 4 th infusion	Week _____	_____ % of target dose*	_____ grams
<input type="checkbox"/> 5 th infusion	Week _____	_____ % of target dose*	_____ grams

- Dispense: Sizes & quantities sufficient. Ramp doses: x 1 refill each. HyQvia target dose refill as directed x 1 year.
- For each full or partial vial of Immune Globulin (IG) 10%, administer the entire contents of accompanying Hyaluronidase. Administer Hyaluronidase at a rate of 1 - 2 ml/min via subcutaneous push. Immediately thereafter administer Immune Globulin (IG) 10%.
- Round dose to nearest vial size. Immune Globulin (IG) 10% manufactured as 100 mg/ml solution in sizes of 2.5 gm/25 ml, 5 gm/50 ml, 10 gm/100 ml, 20 gm/200 ml & 30 gm/300 ml
- Target dose may be administered over multiple days in divided doses with 48-72 hours between doses based on maximum daily dose or infusion tolerability as assessed by pharmacist. Decline
- Pharmacist/Nursing to calculate infusion parameters, number of sites, and administration location per package insert and adjust based on patient tolerance. May infuse +/- 4 days to allow for patient scheduling.

Ancillary Orders:

- Acetaminophen _____ mg PO 30 min before infusion. Patient may use own supply or patient may decline.
- Diphenhydramine _____ mg PO 30 min before infusion. Patient may use own supply or patient may decline.
- Lidocaine 2.5%/prilocaine 2.5% cream 30 gm tube: Apply to SUBQ site(s) during access pm.
- Other: _____
 - Anaphylaxis Orders: Epinephrine Auto-Injector 0.3 mg (≥ 30 kg) or 0.15 mg (15 to 30 kg) 2-Pack – Inject 1 dose IM x 1 PRN anaphylactic reaction, repeat x1 PRN.
 - Skilled nurse to assess and teach self-administration of SUBQ medication where appropriate. Nurse will provide ongoing support, including administration of medication, PRN.
 - Refill above ancillary orders as directed x 1 year.

If patient is seen within a provider led infusion clinic, Option Care Health's infusion reaction management policy, skilled nursing plan of treatment, and IV flush administration will be followed per provider oversight. No individual anaphylaxis kit will be dispensed.

I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.

Prescriber Signature: _____ **Dispense as written** **Date:** _____

Prescriber Name: _____ Address: _____ City: _____ State: _____ Zip: _____ Phone: _____ Fax: _____	Specialty: _____ Office Contact: _____ Hospital/Clinic: _____
--	---

Fax completed form, insurance information, and clinical documentation to: 713-983-4647

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. **IMPORTANT WARNING:** This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.